Novel protein-loaded chondroitin sulfate-N-[(2-hydroxy-3-trimethylammonium)propyl]chitosan nanoparticles with reverse zeta potential: preparation, characterization, and ex vivo assessment

2015 ◽  
Vol 3 (44) ◽  
pp. 8729-8737 ◽  
Author(s):  
Tsung-Neng Tsai ◽  
Hui-Ju Yen ◽  
Cheng-cheung Chen ◽  
Ying-chuan Chen ◽  
Yen-an Young ◽  
...  
Keyword(s):  
Zeta Potential ◽  
Chondroitin Sulfate ◽  
Ex Vivo ◽  
Chitosan Nanoparticles ◽  
Charged Nanoparticles ◽  
Potential Preparation ◽  
Novel Protein

Positively and negatively surface charged nanoparticles were prepared by a facile PEC method composed of chondroitin sulfate and N-[(2-hydroxy-3-trimethylammonium)propyl]chitosan.

Novel protein-loaded chondroitin sulfate–chitosan nanoparticles: Preparation and characterization

2011 ◽  
Vol 7 (10) ◽  
pp. 3804-3812 ◽  
Author(s):  
Ming-kung Yeh ◽  
Kuang-ming Cheng ◽  
Chieh-shen Hu ◽  
Yu-chuan Huang ◽  
Jenn-jong Young
Keyword(s):  
Chondroitin Sulfate ◽  
Chitosan Nanoparticles ◽  
Novel Protein

scholarly journals Targeted Delivery of Amantadine-loaded Methacrylate Nanosphere-ligands for the Potential Treatment of Amyotrophic Lateral Sclerosis

2018 ◽  
Vol 21 ◽  
pp. 94-109 ◽  
Author(s):  
Zamanzima Mazibuko ◽  
Sunaina Indermun ◽  
Mershen Govender ◽  
Pradeep Kumar ◽  
Lisa C Du Toit ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Zeta Potential ◽  
Targeted Delivery ◽  
Ex Vivo ◽  
Release Kinetics ◽  
Burst Release ◽  
Prolonged Release ◽  
Chelating Ligand ◽  
Study Results ◽  
Lateral Sclerosis

Purpose. This study aimed to develop and analyse poly(DL-lactic acid)-methacrylic acid nanospheres bound to the chelating ligand diethylenetriaminepentaacetic acid (DTPA)  for the targeted delivery of amantadine in Amyotrophic Lateral Sclerosis (ALS). Methods. The nanospheres were prepared by a double emulsion solvent evaporation technique statistically optimized employing a 3-Factor Box-Behnken experimental design. Analysis of the particle size, zeta potential, polydispersity (Pdl), morphology, drug entrapment and drug release kinetics were carried out. Results. The prepared nanospheres were determined to have particle sizes ranging from 68.31 to 113.6 nm (Pdl ≤ 0.5). An initial burst release (50% of amantadine released in 24 hr) was also obtained, followed by a prolonged release phase of amantadine over 72 hr. Successful conjugation of the chelating ligand onto the surface of the optimised nanospheres was thereafter achieved and confirmed by TEM. The synthesized modified nanospheres were spherical in shape, 105.6 nm in size, with a PdI of 0.24 and zeta potential of -28.0 mV. Conjugation efficiency was determined to be 74%. In vitro and ex vivo cell study results confirmed the intracellular uptake of the modified nanospheres by the NSC-34 cell line and the non-cytotoxicity of the synthesized nanospheres. Conclusions. Biocompatible amantadine-loaded nanospheres were successfully designed, characterized and optimized employing the randomized Box-Behnken statistical design. Delivery of amantadine over 72 hrs was achieved, with the nanospheres being of a size capable of internalization by the NSC- 34 cells. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

scholarly journals Ex-vivo Ex-Vivo Absorption Study of a Novel Dabigatran Etexilate Loaded Nanostructured Lipid Carrier Using Non-Everted Intestinal Sac Model

2019 ◽  
Vol 28 (2) ◽  
pp. 37-45
Author(s):  
Haithem N Abed ◽  
Ahmed A. Hussein
Keyword(s):  
Particle Size ◽  
Oleic Acid ◽  
Zeta Potential ◽  
Oral Absorption ◽  
Ex Vivo ◽  
Dabigatran Etexilate ◽  
Entrapment Efficiency ◽  
Nanostructured Lipid Carrier ◽  
Loading Capacity ◽  
Intestinal Permeation

Abstract The purpose of our study was to develop Dabigatran Etexilate loaded nanostructured lipid carriers (DE-NLCs) using Glyceryl monostearate and Oleic acid as lipid matrix, and to estimate the potential of the developed delivery system to improve oral absorption of low bioavailability drug, different Oleic acid ratios effect on particle size, zeta potential, entrapment efficiency and loading capacity were studied, the optimized DE-NLCs shows a particle size within the nanorange, the zeta potential (ZP) was 33.81±0.73mV with drug entrapment efficiency (EE%) of  92.42±2.31% and a loading capacity (DL%) of 7.69±0.17%. about 92% of drug was released in 24hr in a controlled manner, the ex-vivo intestinal permeation study using the non-everted sac model shows four folds increment in the permeation of DE-NLCs compared to dabigatran etexilate suspension (DE-S).

Preparation and optimization of controlled release nanoparticles containing cefixime using Central Composite design: An attempt to enrich its antimicrobial activity

2021 ◽  
Vol 18 ◽  
Author(s):  
Mohammad Ali Mahjoub ◽  
Pedram Ebrahimnejad ◽  
Fatemeh Shahlaee ◽  
Pouneh Ebrahimi ◽  
Zaynab Sadeghi-Ghadi
Keyword(s):  
Central Composite Design ◽  
Dissolution Rate ◽  
Ex Vivo ◽  
Chitosan Nanoparticles ◽  
Amorphous State ◽  
Scanning Tunneling ◽  
Release Kinetic ◽  
Calorimetric Analysis ◽  
Cell Culture Study ◽  
Central Composite

Background: Due to the increased resistance against existing antibiotics, research is essential to discover new and alternative ways to control infections induced by resistant pathogens. Objective: The goal of the current scrutinization was to enrich the dissolution rate and antibacterial property of cefixime (CEF) orally. Methods: To achieve the desired results, chitosan nanoparticles (NPs) containing CEF were fabricated using the ionic gelation method. Central Composite design has been applied to get the optimal formulation for the delivery of CEF. The effect of three variables such as the concentration of chitosan, tripolyphosphate, and tween 80 on the characteristics of NPs was evaluated. Results: The optimized NPs were a relatively monodispersed size distribution with an average diameter of 193 nm and a zeta potential of about 11 mV. The scanning tunneling microscope confirmed the size of NPs. The surface morphology of NPs was observed by scanning electron microscopy. The calorimetric analysis indicated the amorphous state of cefixime in the formulation. The dissolution rate of NPs in aqueous media was acceptable and the model of release kinetic for CEF from NPs followed the Peppas model. The potency of CEF in NPs against various types of bacteria was hopefully efficient. The ex- vivo release study demonstrated higher penetration of NPs from the rat intestine compared to free drug. The cell culture study showed the safety of the optimized formulation. Conclusion: It was concluded that CLN could be considered as a prospering system for the controlled delivery of CEF with advantaging its antibacterial effectiveness.

Chitosan nanoparticles loading oxaliplatin as a mucoadhesive topical treatment of oral tumors: Iontophoresis further enhances drug delivery ex vivo

2020 ◽  
Vol 154 ◽  
pp. 1265-1275 ◽  
Author(s):  
Breno N. Matos ◽  
Maíra N. Pereira ◽  
Martha de O. Bravo ◽  
Marcilio Cunha-Filho ◽  
Felipe Saldanha-Araújo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Topical Treatment ◽  
Ex Vivo ◽  
Chitosan Nanoparticles ◽  
Oral Tumors

scholarly journals Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study

Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 197 ◽  
Author(s):  
Doaa Hassan ◽  
Rehab Abdelmonem ◽  
Menna Abdellatif
Keyword(s):  
Particle Size ◽  
Intraocular Pressure ◽  
Zeta Potential ◽  
Ex Vivo ◽  
Entrapment Efficiency ◽  
Molar Ratio ◽  
Duration Of Action ◽  
Corneal Permeability ◽  
Glaucoma Treatment

This study evaluated the efficacy of cationic nanoparticle (leciplex) to deliver carvedilol to ocular surface for glaucoma treatment as recent studies pointed out the effect of topical carvedilol on intraocular pressure, therefore carvedilol loaded leciplex formulae were prepared using soy phosphatidyl choline (SPC) and cationic surfactant (CTAB/DDAB) and characterized for morphology, entrapment efficiency, particle size, zeta potential and ex-vivo corneal permeation. Then the selected formula was evaluated via in-vivo studies in comparison with carvedilol solution. Leciplex nanoparticles appeared spherical in shape with entrapment efficiency exceeded 95% in all formulae. Leciplex formula composed of SPC and DDAB in (1:1) molar ratio showed the smallest particle size (16.04 ± 1.2 nm), highest zeta potential value (53.9 ± 0.91 mv) and highest apparent corneal permeability coefficient (0.1157 cm/h). Carvedilol leciplex reduced intraocular pressure (IOP) to normal range in ocular hypertensive rabbits after 30 min and duration of action lasted for 24 h, while carvedilol solution reduced IOP to normal value after 60 min and duration of action lasted for 6 h. Furthermore, histological examination of eyeballs of rabbits treated with carvedilol leciplex showed improvement of retinal atrophy of glaucomatous eyes. This study concluded that leciplex improve transcorneal permeation and bioavailability of carvedilol.

scholarly journals Enhanced Antifungal Effect of Chitosan/Pepper Tree (Schinus molle) Essential Oil Bionanocomposites on the Viability of Aspergillus parasiticus Spores

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Ana Guadalupe Luque-Alcaraz ◽  
Mario Onofre Cortez-Rocha ◽  
Carlos Arturo Velázquez-Contreras ◽  
Ana Lilian Acosta-Silva ◽  
Hisila del Carmen Santacruz-Ortega ◽  
...  
Keyword(s):  
Essential Oil ◽  
Zeta Potential ◽  
Aspergillus Parasiticus ◽  
Chemical Interaction ◽  
Chitosan Nanoparticles ◽  
Spherical Particles ◽  
Schinus Molle ◽  
Feasible Alternative ◽  
Pepper Tree

Chitosan nanoparticles (CS) and chitosan/pepper tree (Schinus molle) essential oil (CS-EO) bionanocomposites were synthesized by nanoprecipitation method and the in vitro antifungal activity against Aspergillus parasiticus spores was evaluated. The shape and size were evaluated by scanning electron microscopy (SEM) and dynamic light scattering (DLS). The surface charge was determined by assessing the zeta potential and the inclusion of essential oil in bionanocomposites using Fourier transform infrared spectroscopy (FT-IR). The effect on cell viability of the fungus was evaluated using the XTT technique and morphometric analysis by image processing. SEM and DLS analysis indicated that spherical particles with larger diameters for CS-EO biocomposites were observed. Zeta potential values were higher (+11.1 ± 1.60 mV) for CS nanoparticles. Results suggest a chemical interaction between chitosan and pepper tree essential oil. The highest concentration of CS-EO complex caused a larger (40–50%) decrease in A. parasiticus viability. The inclusion of pepper tree oil in CS nanoparticles is a feasible alternative to obtain antifungal biocomposites, where the activity that each compound presents individually is strengthened.

scholarly journals Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

2015 ◽  
Vol 51 (2) ◽  
pp. 467-477 ◽  
Author(s):  
Abdul Baquee Ahmed ◽  
Ranjit Konwar ◽  
Rupa Sengupta
Keyword(s):  
Particle Size ◽  
Zeta Potential ◽  
Oral Bioavailability ◽  
Chitosan Nanoparticles ◽  
Rabbit Model ◽  
Pharmacokinetic Studies ◽  
Release Formulation ◽  
Atorvastatin Calcium

<p>In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, <italic>in vitro</italic> release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva<sup>(r))</sup> in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. <italic>In vitro</italic> release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva<sup>(r))</sup>. Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model.</p>

scholarly journals In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation

Nanomaterials ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 709 ◽  
Author(s):  
Blanca Lorenzo-Veiga ◽  
Patricia Diaz-Rodriguez ◽  
Carmen Alvarez-Lorenzo ◽  
Thorsteinn Loftsson ◽  
Hakon Hrafn Sigurdsson
Keyword(s):  
Zeta Potential ◽  
Physicochemical Properties ◽  
Inflammatory Mediators ◽  
Ex Vivo ◽  
Posterior Segment ◽  
Inflammatory Activity ◽  
Commercial Formulation ◽  
Anti Inflammatory ◽  
Negative Zeta Potential

The aim of this study was to design and evaluate novel cyclodextrin (CD)-based aggregate formulations to efficiently deliver nepafenac topically to the eye structure, to treat inflammation and increase nepafenac levels in the posterior segment, thus attenuating the response of inflammatory mediators. The physicochemical properties of nine aggregate formulations containing nepafenac/γ-CD/hydroxypropyl-β (HPβ)-CD complexes as well as their rheological properties, mucoadhesion, ocular irritancy, corneal and scleral permeability, and anti-inflammatory activity were investigated in detail. The results were compared with a commercially available nepafenac suspension, Nevanac® 3 mg/mL. All formulations showed microparticles, neutral pH, and negative zeta potential (–6 to –27 mV). They were non-irritating and nontoxic and showed high permeation through bovine sclera. Formulations containing carboxymethyl cellulose (CMC) showed greater anti-inflammatory activity, even higher than the commercial formulation, Nevanac® 0.3%. The optimized formulations represent an opportunity for topical instillation of drugs to the posterior segment of the eye.

Sign in / Sign up

Export Citation Format

Share Document